Lv1
30 积分 2022-07-22 加入
On comparing competing risks using the ratio of their cumulative incidence functions
28天前
已完结
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
2个月前
已完结
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
2个月前
已完结
Neoadjuvant chemotherapy for ovarian cancer: Avoiding ‘needless hurt’?
3个月前
已完结
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial
3个月前
已完结
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
3个月前
已完结
Sentinel lymph node mapping in early-stage ovarian cancer: surgical technique in 10 steps
3个月前
已完结
Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer
4个月前
已完结
Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis
4个月前
已完结
Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer
4个月前
已完结
皖公网安备34019202002308
